Senior Management

Dr Jenny Harry - Chief Executive Officer

Jenny Harry has over 12 years' experience in executive management, securing global partnerships, commercialising technologies and raising capital in the biotechnology sector. In her previous role, as CEO and Managing Director of Tyrian Diagnostics (ASX:TDX) Jenny transformed the company from an R&D business to a diagnostics business, and oversaw development of the company's first diagnostic products through to commercialisation and early revenue generation. Jenny's corporate experience extends to leading a multi-functional, multi-site organisation, building high performing teams, strategic planning and product portfolio development, negotiating agreements and establishing commercial partnerships, and analysing investment opportunities.

Jenny received a PhD in developmental biology from Macquarie University, Sydney, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors.

Dr Barry Marshall - Scientific Director

Dr Marshall is a world authority on Helicobacter pylori. He is the co-discoverer of the H. pylori organism, co-recipient of the 2005 Nobel Prize for Medicine and Physiology as well as numerous other prestigious awards (including the 1995 Lasker Award) and elected a Fellow of the Royal Society in 1999 and US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discoveries have revolutionised the management of peptic ulcer disease and resulted in the cure for peptic ulcers. Related research into a diagnostic leading to patentable technology resulted in the formation of TriMed Distributors Pty Ltd, a successful private company. Dr Marshall is the founder of Ondek. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.

Dr. Mohammed Benghezal - Chief Scientist

Dr Benghezal is a biochemist and a molecular biologist with extensive experience in the biotechnology industry. Most recently he was Head of Genetics and Biochemistry at Athelas Ltd, based in Geneva, Switzerland. He was involved in the technology transfer from the University of Geneva, the launch of the company and the subsequent trade sale of the company. His ongoing role involved the establishment of a host-pathogen interaction model for high-throughput identification of virulence bacterial genes and antibacterial molecules, and the development of relevant rodent infection models for the validation of the genes and antibacterial molecules. Dr. Benghezal is the Chief Scientist of Ondek and he also holds an Adjunct Associate Professor position at the University of Western Australia.

Dr Alma Fulurija - Head Immunology and Translational Research

Dr Fulurija is an Australian graduate from Perth, attracted back from Switzerland after a successful career in the fields of novel vaccines and immunology. She has a wide variety of experience in vaccine development and immunotherapy including most recently with Cytos Biotechnology, voted Switzerland's most exciting new biotechnology start-up float in 2005. She has also worked at the WHO Centre for Neonatal Immunology and Vaccinology in Geneva and has collaborated with Novartis and Pfizer on a number of projects. Dr Fulurija's key expertise lies in in vivo pre-clinical models, as well as clinical and regulatory requirements for Phase I/II clinical trials. Dr Fulurija is Ondek's Head of Immunology and Translational Research and also holds an Adjunct Senior Lecturer position at the University of Western Australia.

Dr. Hans-Olof Nilsson - Senior Scientist Microbiology

Hans-Olof Nilsson holds a Masters (1999) and PhD Degree (2004) in Medical Microbiology from the Department of Laboratory Medicine, Lund University, Sweden. Dr Nilsson has extensive expertise in medical microbiology, particularly with Helicobacter species. His research has focused on virulence factors of pathogenic group A and B Streptococci and Helicobacter pylori and Helicobacter bacteriology and pathogenesis, including transmission and environmental survival. Dr. Nilsson has also developed experimental H. pylori and natural Helicobacter species rodent models and has applied DNA-based technology and genotyping methods to characterise Helicobacter infections. Dr Nilsson joined Ondek Pty. Ltd. in March 2009.